HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 14, 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
August 08, 2023 16:05 ET
|
Icosavax, Inc.
- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
August 07, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Nasal Vaccines Market Anticipated to Reach US$ 742.6 Million, Globally, by 2030 at 8.6% CAGR: Coherent Market Insights (CMI)
July 25, 2023 05:06 ET
|
CMI
Burlingame, July 25, 2023 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, “Nasal Vaccines Market, By Vaccine type (Live attenuated vaccines, Inactivated vaccines, Subunit,...
The Advancing Health Online (AHO) Initiative Invests $5M through the Vaccine Confidence Fund for Research to Understand How to Boost Vaccination Confidence through Social Media
June 27, 2023 15:00 ET
|
Global Impact
ALEXANDRIA, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Global Impact, as fiscal sponsor for the Advancing Health Online (AHO) Initiative, is pleased to announce the selection of 11 organizations that...
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
June 20, 2023 08:00 ET
|
Icosavax, Inc.
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...
Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award
June 06, 2023 06:00 ET
|
Sabin Vaccine Institute
WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis...
Dyadic to Participate at Upcoming Events in June
June 01, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
May 31, 2023 12:25 ET
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
May 22, 2023 17:53 ET
|
Icosavax, Inc.
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...